A table for lipid targets and ranges based on the CPG and ACG documents below for reference.
Table for Lipid Reference Ranges
|
Risk Category
|
Risk Profile
|
Therapeutic Targets for LDL-C*#
|
Optimal HDL-C Ranges*
|
Optimal TG Levels*
|
|
High Risk |
> 20% 10-year risk (SMFRS) ASCVD DM (poor control/complications) FH ( >40 years/additional CV risk factor) |
<1.8 mmol/l Or <70 mg/dl |
1.0mmol/l to 2.3 mmol/l Or 40 mg/dl to 90mg/dl |
≤ 1.7 mmol/l Or ≤ 150mg/dl |
|
Intermediate Risk |
10-20% 10-year risk DM (well controlled, no complications) FH (no additional CV risk factor) CKD (Egfr <60ml/min, ACR > 3mg/mmol) |
1.8 mmol/l to <2.6 mmol/l Or 70 to <100 mg/dl |
≤ 1.7 mmol/l Or ≤ 150mg/dl |
|
|
Borderline or Low Risk |
<10% 1—year risk |
2.6 mmol/l to <3.4 mmol/l Or 100 mg to <130mg/dl |
≤ 2.3 mmol/l Or ≤ 200 mg/dl |
Notes:
*ACR - urinary albumin to creatine ratio, ASCVD - atherosclerotic cardiovascular disease, CV- cardiovascular, CKD - Chronic Kidney Disease, DM - diabetes mellitus, FH - familial hyperlipidemia, eGFR - estimated glomerular filtration rate, LDL-C - low density lipoprotein cholesterol, SG-FRS - Singapore modified Framingham risk score
Based on Clinical Practice Guidelines on Management of Lipids, Chapter of Cardiologists, Academy of Medicine, 2023 *and ACE Clinical Guidance on Lipid Management, MOH 2023# ( jointly released on 15 Dec 2023)
Credits:
From Parkway Laboratories Memorandum dated 8 August 2025, Updates to Reference Interval for Lipid Profile Dr Daniel Chong, Chapter Chair, Chapter of Cardiologists, Academy of Medicine, Singapore Dr Michael Lim, Chairman, Clinical Practice Guidelines for Management of Lipids Committee, Academy of Medicine, Singapore
